ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1930 • ACR Convergence 2025

    Can a Multinational Awareness Campaign Improve Referral Rates and Reduce Diagnostic Delays in Patients with Chronic Inflammatory Rheumatic Diseases? The Impact of a Prospective Interventional Study

    Nelly Ziade1, Karen Mechleb2, Fatima Alnaimat3, Sherif Gamal4, Avin Maroof5, Bassel Elzorkany6, Manal Mashaleh7, Manal El Rakawi8, Mahmoud Adly9, Lina Elkibbi10, ERRAOUI Mariam11, Krystel Aouad12, Chafika Haouichat13, Nizar Abdullateef14, ASAL ADNAN RIDHA15, Fatemah Baron16 and Ihsane Hmamouchi17, 1Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, 2Saint Joseph University Beirut, Beirut, Lebanon, 3The University of Jordan, amman, Jordan, 4Cairo University, Cairo, Egypt, 5University of Kurdistan Hawler, Erbil, Iraq, 6Private (BZRC), Cairo, Egypt, 7Al Saudi Hospital, Amman, Jordan, 8Djillali Bounaama University Hospital, Algiers, Algeria, Algiers, Algeria, 9Ministry of Health, Kuwait, Kuwait, Saad Elabdulla, Kuwait, 10Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, 11CHU Agadir, Agadir, Morocco, 12Department of Rheumatology, Saint George Hospital University Medical Center, Beirut, Lebanon, 13Djillali Bounaama University Hospital, Algiers, Algeria, 14Baghdad College of Medicine, Baghdad, Iraq, 15Baghdad Teaching Hospital, Baghdad, Iraq, 16Al-Jahra Hospital, Kuwait, Kuwait, Kuwait, Kuwait, 17Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco

    Background/Purpose: Delayed diagnosis and treatment in chronic inflammatory rheumatic diseases (CIRDs), including rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA), is associated with…
  • Abstract Number: 1751 • ACR Convergence 2025

    Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study

    Gregory McDermott1, Xiaosong Wang2, Misti Paudel3, Ying Qi4, Emily Kowalski5, Grace Qian6, Liya Sisay Getachew5, Kevin Mueller6, Alene Saavedra6, Lauren O'Keeffe6, Natalie Davis1, Alison Puri7, Kathleen Vanni6, Caleb Bolden8, Tina Mahajan9, Erica Mulcaire-Jones10, Neda Kortam11, Pierre Antoine Juge12, Tracy J. Doyle13, Marcy Bolster14, Kevin Deane15, Dinesh Khanna10, Bryant England9, Raul San Jose Estepar6, George Washko6 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Brookline, MA, 2Brigham and Women's Hospital, Natick, MA, 3Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 4Brigham and Women’s Hospital, Boston, 5Brigham and Women's Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, 7Boston University, Brookline, MA, 8Massachusetts General Hospital, Boston, 9University of Nebraska Medical Center, Omaha, NE, 10University of Michigan, Ann Arbor, MI, 11University of Michigan, Ann Arbor, 12Hopital Bichat, APHP, Paris, France, 13Brigham and Women's Hospital, West Roxbury, MA, 14Massachusetts General Hospital, Concord, MA, 15University of Colorado Denver Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Quantitative computed tomography (QCT) methods using machine learning have been developed to automatically quantify parenchymal lung features on chest CT imaging. QCT can detect…
  • Abstract Number: 1677 • ACR Convergence 2025

    First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care

    Task Toyoda1, Kerem Abacar1, Farag Shuweihdi2, Megan Sheridan3, Jacqueline Nam3, Ai Lyn Tan4, Lesley-Anne Bissell3, Paul Emery5 and Kulveer Mankia5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, 2Dental Translational and Clinical Research Unit, School of Medicine, University of Leeds, Leeds, England, United Kingdom, 3Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, 4NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, 5University of Leeds, Leeds, England, United Kingdom

    Background/Purpose: While conventional synthetic DMARDs (csDMARDs) remain first line therapy in early RA, most patients do not achieve sustained remission, and a subgroup develop difficult-to-treat…
  • Abstract Number: 1372 • ACR Convergence 2025

    Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study

    Sungwon Ko1, Young-Eun Kim1, Soo Min Ahn1, Ji Seon Oh1, Yong-Gil Kim1, Chang-Keun Lee2, Bin Yoo1 and Seokchan Hong1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, 2Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea

    Background/Purpose: Janus kinase (JAK) inhibitors are recommended for patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic or biologic disease-modifying antirheumatic…
  • Abstract Number: 1354 • ACR Convergence 2025

    Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial

    Hongtao Jin, Huifang Guo, Yuxiang Han and Meng Ding, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic)

    Background/Purpose: Joint swelling and tenderness are major symptoms of rheumatoid arthritis (RA). This post-hoc analysis evaluated the effect of ivarmacitinib (SHR0302), a selective Janus kinase…
  • Abstract Number: 1337 • ACR Convergence 2025

    The Association Between Glucagon-Like Peptide-1 Receptor Agonist and Rheumatoid Arthritis: A Population-Based Case Control Study

    Ariel Israel1, Fadi Hassan2, Jalal Kurtam2, Jamal Awad2, Eugene Merzon1 and Mohammad Naffaa3, 1Leumit Health Services, Tel-Aviv, Israel, 2Galilee Medical Center, Nahariya, Israel, 3The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel

    Background/Purpose: The increasing use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) for diabetes mellitus (DM) and weight loss has the potential modify the risk for rheumatoid…
  • Abstract Number: 1321 • ACR Convergence 2025

    Efficacy and safety of janus kinase inhibitors in diffuse interstitial lung disease in rheumatoid arthritis. Systematic review

    Olga Compán1, Marta Ibañez2, Olga Martínez3, Carolina Cristina Chacón4, Ricardo López Pérez3, Borja Felices López3, Belén Miguel Ibáñez3, Laura Blanco4, Sergio Cimadevila Santiago3, Ana Isabel Turrión Nieves3, Manuel Cipriano Martin Martinez3, Cristina Hidalgo Calleja4, Carlos Montilla4 and Susana Gómez4, 1Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, 37191, Spain, 2Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 3Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 4Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a relatively common serious extra-articular complication in rheumatoid arthritis (RA). Although there have been great advances, we do not…
  • Abstract Number: 1267 • ACR Convergence 2025

    Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App

    Leah Santacroce1, Misti Paudel2 and Daniel Solomon3, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 3Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Patient Reported Outcomes (PROs) collected via a mobile health application (App) can provide valuable insight into the health of patients with Rheumatoid Arthritis (RA).…
  • Abstract Number: 1102 • ACR Convergence 2025

    Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.

    Julia Barasch1, Nilasha Ghosh2, Deanna Jannat-Khah3, Kyle Ge4, Jeffrey Curtis5 and Anne R. Bass3, 1NYP- Weill Cornell, New York, 2Hospital for Special Surgery, New York, NY, 3Hospital For Special Surgery, New York, NY, 4Hospital for Special Surgery, New York, 5Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL

    Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…
  • Abstract Number: 1027 • ACR Convergence 2025

    GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Nick McCormick1, Jingyi Zhang2, Emily Holladay2, Fenglong Xie3 and Jeffrey Curtis4, 1Auburn University, Auburn, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3The University of Alabama at Birmingham, Birmingham, AL, 4Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL

    Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
  • Abstract Number: 0925 • ACR Convergence 2025

    Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis

    Megan M. Hanlon1, Catherine Manning1, Kevin Wei1, Ursula Fearon2 and Ellen M. Gravallese3, 1Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 2Trinity College Dublin, Dublin, Dublin, Ireland, 3Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Synovial tissue macrophages (STMs) represent a mixed population of cells contributing to the pathogenesis of rheumatoid arthritis (RA). We identified an enrichment of Secreted…
  • Abstract Number: 0834 • ACR Convergence 2025

    Heterogeneity in the Association of Genetic Risk for Rheumatoid Arthritis and Resultant Rheumatoid Arthritis Phenotypes

    Thomas Riley1, Austin Wheeler2, Bryant England2, Grant Cannon3, Brian Sauer4, Gary Kunkel5, Katherine Wysham6, Beth Wallace7, Paul Monach8, Andreas Reimold9, Gail Kerr10, Isaac Smith11, John Richards12, Iris Lee13, Geoffrey Thiele2, Rui Xiao1, Scott Damrauer14, Michael Levin14, Michael George1, Ted Mikuls2 and Joshua Baker1, 1University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3University of Utah and Salt Lake City VA, Salt Lake City, UT, 4Salt Lake City VA/University of Utah, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 7Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 8VA Boston Healthcare System, Boston, MA, 9Dallas VA Medical Center, Dallas, TX, 10Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 11Duke University Hospital, Durham, NC, 12Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 13Washington University in St Louis, Saint Louis, MO, 14University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA

    Background/Purpose: The impact of genetic risk factors on rheumatoid arthritis (RA) phenotype is incompletely understood. Comparing individual genetic variants associated with RA susceptibility to a…
  • Abstract Number: 0775 • ACR Convergence 2025

    Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression

    Anastasiia Phothisane1, Tulsi Joishy2, Carolina Ramirez-Becerra1, Zuofei Wang2, Qiong Wu3, Jennifer Seifert4, Marie Feser5, Jill Norris6, Kristen Demoruelle7, LauraKay Moss5, Kevin Deane8, V. Michael Holers9 and Michelle Ormseth2, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, 3University of Virginia, Charlottesville, VA, 4University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 5University of Colorado Anschutz Medical Campus, Aurora, CO, 6Colorado School of Public Health, Denver, CO, 7University of Colorado Anschutz Medical Campus, Golden, CO, 8University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 9University of Colorado Anschutz Medical Campus, Aurora

    Background/Purpose: Microbial small RNAs (sRNAs) can regulate human genes, often with anti-inflammatory effects. We previously showed that an increased plasma concentration of a tRNA-derived RNA…
  • Abstract Number: 0490 • ACR Convergence 2025

    Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis

    Li Liu1, Xue-Mei Zhang1, Zhi-Chun Gu1 and Jia Li2, 1Ren Ji Hospital, Shanghai Jiao Tong University School Of Medicine, Pu Dong Xin Qu, Shanghai, China (People's Republic), 2Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)

    Background/Purpose: This study aimed to evaluate the infection risks in patients with rheumatoid arthritis (RA) treated with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),…
  • Abstract Number: 0474 • ACR Convergence 2025

    Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation

    Joseph Nathan1, Bayram Farisogullari2, Nicholas Jones3, Mohammad Ayoub3, James Brown3, Sarah Levy3, James Brader4, Ayse Ersoy4, Blossom Israni4, Mark Lloyd4, Afzal Latheef5, Diane Hill5, Amybel Taylor6, Darshani Arachchige6, Hlaing Chitsu6, Helen Linklater6, Kunal Lather7, Luke Gompels7, Eman Elfar8, Ritu Malaiya8, Pedro Machado9 and Patrick Kiely10, 1St George's Hospital, London, United Kingdom, 2University College London, London, 3Croydon Health Services NHS Trust, Croydon, England, United Kingdom, 4Frimley Health NHS Foundation Trust, Frimley, England, United Kingdom, 5St George's University Hospitals NHS Foundation Trust, London, England, United Kingdom, 6Surrey and Sussex Healthcare NHS Trust, Redhill, England, United Kingdom, 7Somerset NHS Foundation Trust, Taunton, England, United Kingdom, 8Epsom and St Helier University Hospitals NHS Trust, Carshalton, England, United Kingdom, 9Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 10St George's University Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: The use of Janus Kinase inhibitors (JAKi) to treat RA and PsA in a real-world setting has not been well described. Our aim was…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology